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1 Which anti-VEGF agents do we use? {#s1}
===================================

We use bevazucimab (Avastin) -- the dose used is 2.5 mg (0.1 ml). This anti-VEGF agent is used because of its:

-   proven efficacy and effectiveness (CATT & IVAN studies)

-   low cost, making it affordable for our patients.
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2 What are the indications? {#s2}
===========================

-   Vitreous haemorrhage secondary to proliferative diabetic retinopathy -- particularly when there has been no previous laser.

-   Prior to vitrectomy for proliferative diabetic retinopathy.

-   Clinically significant macular oedema due to diabetic retinopathy.

-   Macular oedema secondary to branch or central retinal vein occlusion.

-   Exudative age-related macular degeneration.

-   Neovascular glaucoma.

3 Who gives the injections? {#s3}
===========================

Intra-vitreal injections are always given by an ophthalmologist, for example:

-   retina specialists

-   retina subspecialty trainees

-   ophthalmology residents in the retinal service.

4 Are anti-VEGF agents used without OCT? {#s4}
========================================

Anti VEGF agents are used without OCT in selected cases:

-   vitreous haemorrhage secondary to proliferative diabetic retinopathy -- particularly when there has been no previous laser

-   prior to vitrectomy for proliferative diabetic retinopathy

-   clinically significant macular oedema due to diabetic retinopathy

-   neovascular glaucoma.

5 What are the outcomes? {#s5}
========================

Clinical experience has been very positive and we believe this is a cost-effective treatment for our patients.

**Vitreous haemorrhage secondary to proliferative diabetic retinopathy:** We have been pleased with our results. Anti-angiogenic therapy reduces the vitreous haemorrhage in many patients with diabetic retinopathy, allowing us to apply laser and avoid vitrectomy surgery.

**Prior to vitrectomy for proliferative diabetic retinopathy:** Application 3--5 days before surgery reduces the risk of intra-operative and postoperative bleeding.

**Neovascular glaucoma:** In these patients, we are careful to avoid further increases in the IOP. When the rubeosis regresses we apply pan-retinal laser, giving us more control of the iris neovascularisation.

**Clinically significant macular oedema:** In clinically significant macular oedema due to diabetic retinopathy, we normally apply three doses of Avastin with 1-month intervals between injections. After the last injection, a macular OCT is requested and, if the oedema has decreased, we apply focal laser.

**Age-related macular degeneration (AMD):** In patients with exudative AMD, an injection is given every month for several months to improve visual acuity and to control the disease, following the 'treat and extend' protocol.
